Takeda Sees Portfolio As Mostly Pandemic-Resistant
But Some Trials Being Impacted
Takeda says the coronavirus is affecting some of its clinical programs but that many key pipeline assets remain on track, while its existing commercial portfolio is seen as resilient by nature.
